This 56-week, randomized, placebo-controlled trial evaluated the efficacy and safety of combining sustained-release naltrexone (32 mg/day) and bupropion (360 mg/day) with intensive behavior modification (BMOD) in 793 obese adults (mean BMI 36.5 ± 4.2 kg/m²). Participants were randomized in a 1:3 ratio to receive either placebo + BMOD (N=202) or
